Mengjie Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mengjie Chen has a total of 353 co-authors. Here are the top co-authors by number of shared publications:
- Alan Cooper
Yale University School of Medicine, New Haven, CT
15 shared publications - Girish Venkataraman
University of Chicago
15 shared publications - James Godfrey
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
15 shared publications - Joshua D. Brody
Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
15 shared publications - Jovian Yu
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois
15 shared publications - Justin Kline
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
15 shared publications
Latest Publications
- Open Access
RNA accessibility sequencing reveals transcriptome-wide RBP binding and RNA structure
We introduce RAD-seq (RNA Accessibility via Deamination sequencing), a simple and scalable method that quantifies RNA accessibility by protein binding in vivo. RAD-seq uses TadA8.20-mediated adenosine deamination to report the local exposure of each adenosine to its molecular environment, integrating the combined effects of base pairing, RNA folding, and RNA-binding protein (RBP) occupancy in a single experiment. RAD-seq profiles recapitulate known structural signatures, reveal high-resolution RBP footprints, report on the influence of RNA modifications, and capture dynamic remodeling of RNA accessibility during oxidative and heat-shock stress. By integrating RAD-seq with RNA Bind-n-Seq motifs, we detected local enrichment of the RNA N 6 -methyladenosine (m 6 A) methyltransferase recruiter TRA2A following knockdown of the exon junction anchor protein EIF4A3, revealing a potential mechanism that links RNA accessibility to enhanced TRA2A recruitment and m 6 A deposition. Extending this framework, we introduce an unsupervised statistical model that combines RAD-seq with motif priors to infer binding landscapes for multiple RBPs, reproducing the information from numerous CLIP-seq datasets from a single RAD-seq experiment. These results indicate RAD-seq as a generalizable approach for joint profiling of RNA structure and protein occupancy, defining enzymatic RNA accessibility as a new dimension to investigate regulatory elements on RNA.
Open AccessRNA accessibility sequencing reveals transcriptome-wide RBP binding and RNA structure
We introduce RAD-seq (RNA Accessibility via Deamination sequencing), a simple and scalable method that quantifies RNA accessibility by protein binding in vivo. RAD-seq uses TadA8.20-mediated adenosine deamination to report the local exposure of each adenosine to its molecular environment, integrating the combined effects of base pairing, RNA folding, and RNA-binding protein (RBP) occupancy in a single experiment. RAD-seq profiles recapitulate known structural signatures, reveal high-resolution RBP footprints, report on the influence of RNA modifications, and capture dynamic remodeling of RNA accessibility during oxidative and heat-shock stress. By integrating RAD-seq with RNA Bind-n-Seq motifs, we detected local enrichment of the RNA N 6 -methyladenosine (m 6 A) methyltransferase recruiter TRA2A following knockdown of the exon junction anchor protein EIF4A3, revealing a potential mechanism that links RNA accessibility to enhanced TRA2A recruitment and m 6 A deposition. Extending this framework, we introduce an unsupervised statistical model that combines RAD-seq with motif priors to infer binding landscapes for multiple RBPs, reproducing the information from numerous CLIP-seq datasets from a single RAD-seq experiment. These results indicate RAD-seq as a generalizable approach for joint profiling of RNA structure and protein occupancy, defining enzymatic RNA accessibility as a new dimension to investigate regulatory elements on RNA.
- Open Access
Gut Microbiota-derived Acetate Safeguards the Colonic Epithelial Acetyl-CoA Reserve to Avert Colonic Senescence
Aging is a major driver of tissue senescence, but little is known about the development of age-unrelated tissue senescence. Here we show that nucleocytosolic acetyl-CoA deficiency in colon epithelial cells, caused by Acly ablation and bacterial depletion, triggers age-independent, p53-dependent colonic senescence leading to severe systemic inflammation. Acetate supplementation, acetate-producing bacterial transplantation, targeted depletion of senescent cells or treatment with lysine deacetylase inhibitors blocks colonic senescence and inflammatory injury. Spontaneous colonic senescence develops following simultaneous deletion of epithelial Acly and Acss2, confirming that microbe-derived acetate maintains the epithelial acetyl-CoA pool via ACSS2 to avert colonic senescence. Mechanistically, acetyl-CoA deficiency deprives a cohort of mitochondrial and nuclear proteins of acetylation, leading to increased oxidative stress and DNA repair stress that trigger cellular senescence. Among these proteins, ATP5F1A-K161 acetylation and H4-K5/8 acetylation are required to protect colonic epithelial cells from developing senescence. These observations unveil a previously unknown mechanism that governs colonic senescence.
Open AccessGut Microbiota-derived Acetate Safeguards the Colonic Epithelial Acetyl-CoA Reserve to Avert Colonic Senescence
Aging is a major driver of tissue senescence, but little is known about the development of age-unrelated tissue senescence. Here we show that nucleocytosolic acetyl-CoA deficiency in colon epithelial cells, caused by Acly ablation and bacterial depletion, triggers age-independent, p53-dependent colonic senescence leading to severe systemic inflammation. Acetate supplementation, acetate-producing bacterial transplantation, targeted depletion of senescent cells or treatment with lysine deacetylase inhibitors blocks colonic senescence and inflammatory injury. Spontaneous colonic senescence develops following simultaneous deletion of epithelial Acly and Acss2, confirming that microbe-derived acetate maintains the epithelial acetyl-CoA pool via ACSS2 to avert colonic senescence. Mechanistically, acetyl-CoA deficiency deprives a cohort of mitochondrial and nuclear proteins of acetylation, leading to increased oxidative stress and DNA repair stress that trigger cellular senescence. Among these proteins, ATP5F1A-K161 acetylation and H4-K5/8 acetylation are required to protect colonic epithelial cells from developing senescence. These observations unveil a previously unknown mechanism that governs colonic senescence.
- Open Access
- 13 February 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (1) , 104306
Protocol to perform cell-type-specific transcriptome-wide association study using scPrediXcan framework
- 13 February 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (1) , 104306
Open AccessProtocol to perform cell-type-specific transcriptome-wide association study using scPrediXcan framework
- Open Access
m 6 A-dependent microRNA binding to chromatin-associated RNA for transcriptional activation
For decades, microRNAs (miRNAs) have been canonically viewed as post-transcriptional repressors. We discovered extensive binding of microRNAs to chromatin-associated RNAs (caRNAs) and uncovered an N 6 -methyladenosine (m 6 A)–dependent transcriptional activation mechanism of microRNAs. We show that m 6 A-binding proteins FXR1/2 anchor AGO1/2 at m 6 A-marked caRNAs, where AAGUGC-seed microRNAs function as guide RNAs to direct AGO positioning. This dual anchoring stabilizes the AGO-microRNA/FXR-m 6 A complex at specific loci, which in turn recruits the ATP-dependent chromatin remodeler SMARCA4 (BRG1) to promote local chromatin opening and TET1 for DNA demethylation, respectively. Together, these coordinated activities establish a transcriptionally permissive chromatin environment, enhancing accessibility and transcription across hundreds of genes in diverse cell types. Beyond the AAGUGC-seed family, additional microRNAs and siRNAs also enhance transcription, suggesting that caRNA binding and transcriptional activation may represent a broader property of small RNAs.
Open Accessm 6 A-dependent microRNA binding to chromatin-associated RNA for transcriptional activation
For decades, microRNAs (miRNAs) have been canonically viewed as post-transcriptional repressors. We discovered extensive binding of microRNAs to chromatin-associated RNAs (caRNAs) and uncovered an N 6 -methyladenosine (m 6 A)–dependent transcriptional activation mechanism of microRNAs. We show that m 6 A-binding proteins FXR1/2 anchor AGO1/2 at m 6 A-marked caRNAs, where AAGUGC-seed microRNAs function as guide RNAs to direct AGO positioning. This dual anchoring stabilizes the AGO-microRNA/FXR-m 6 A complex at specific loci, which in turn recruits the ATP-dependent chromatin remodeler SMARCA4 (BRG1) to promote local chromatin opening and TET1 for DNA demethylation, respectively. Together, these coordinated activities establish a transcriptionally permissive chromatin environment, enhancing accessibility and transcription across hundreds of genes in diverse cell types. Beyond the AAGUGC-seed family, additional microRNAs and siRNAs also enhance transcription, suggesting that caRNA binding and transcriptional activation may represent a broader property of small RNAs.
- Open Access
- 23 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies
Next-generation sequencing (NGS) tests are integral to oncology care. To address the need for clinical and NGS data management, interpretation, and reporting, we developed iCatalog for the multi-institutional Individualized Cancer Therapy 2/Genomic Assessment Informs Novel Therapy Consortium (GAIN) pediatric precision oncology (PO) study. We designed iCatalog as a secure, web-based clinical decision support application that stores and integrates clinical, specimen, and molecular data from multiple sources at the patient level. The knowledge base (KB) and centralized patient/test database are intended to manage information for the 825 patients expected to enroll in the GAIN study. User permissions and access are controlled. Gene- and variant-level interpretation is facilitated through linked external resources and an internal KB that can be updated during application use. iCatalog generates editable, study-specific patient reports for each molecular test. Launched to support the GAIN study, iCatalog integrates genomic data from eight NGS platforms, generates 1002 clinical interpretation reports, and stores data for 1194 tests involving 777 patients with pediatric solid tumors across 133 diagnoses. The KB contains pediatric cancer-specific curations, authored by the research team, spanning 581 genes and 2659 variants (including 2146 single-nucleotide variants and insertions-deletions, 235 copy-number variants, 278 structural variants). iCatalog is a robust tool designed and proven to support a PO study. It integrates clinical and genomic data to facilitate the clinical interpretation and reporting of variants identified through NGS testing while maintaining a pediatric-specific KB generated during the study. As a scalable, modular platform, iCatalog can accelerate clinical decision-making and elevate PO insights across studies.
- 23 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessIntroducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies
Next-generation sequencing (NGS) tests are integral to oncology care. To address the need for clinical and NGS data management, interpretation, and reporting, we developed iCatalog for the multi-institutional Individualized Cancer Therapy 2/Genomic Assessment Informs Novel Therapy Consortium (GAIN) pediatric precision oncology (PO) study. We designed iCatalog as a secure, web-based clinical decision support application that stores and integrates clinical, specimen, and molecular data from multiple sources at the patient level. The knowledge base (KB) and centralized patient/test database are intended to manage information for the 825 patients expected to enroll in the GAIN study. User permissions and access are controlled. Gene- and variant-level interpretation is facilitated through linked external resources and an internal KB that can be updated during application use. iCatalog generates editable, study-specific patient reports for each molecular test. Launched to support the GAIN study, iCatalog integrates genomic data from eight NGS platforms, generates 1002 clinical interpretation reports, and stores data for 1194 tests involving 777 patients with pediatric solid tumors across 133 diagnoses. The KB contains pediatric cancer-specific curations, authored by the research team, spanning 581 genes and 2659 variants (including 2146 single-nucleotide variants and insertions-deletions, 235 copy-number variants, 278 structural variants). iCatalog is a robust tool designed and proven to support a PO study. It integrates clinical and genomic data to facilitate the clinical interpretation and reporting of variants identified through NGS testing while maintaining a pediatric-specific KB generated during the study. As a scalable, modular platform, iCatalog can accelerate clinical decision-making and elevate PO insights across studies.
- 9 December 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (1) , 195-205
Multi-region m6A epitranscriptome profiling of the human brain reveals spatial and temporal variation and enrichment of disease-associated loci
N6-methyladenosine (m6A) is a major RNA modification in the brain, regulating neural processes and contributing to disease mechanisms. Despite its importance, regional, age-specific and sex-specific m6A patterns in the human brain are still poorly described. Here, we profiled m6A mRNA modifications in five human brain regions (Brodmann areas 9 and 24, and the caudate, hippocampus and thalamus) across 25 individuals of different ages, ranging from 0 to 71 years old. We uncovered widespread regional differences for m6A patterns in the brain, notably in disease-risk genes, while age-related changes were most prominent in the prefrontal cortex. Integrating m6A data with whole-genome sequencing revealed that m6A modifications are associated with disease-related genetic loci. Our work identifies the spatial and temporal variation in m6A modifications and suggests how they could contribute to neurological disorders.
- 9 December 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (1) , 195-205
Multi-region m6A epitranscriptome profiling of the human brain reveals spatial and temporal variation and enrichment of disease-associated loci
N6-methyladenosine (m6A) is a major RNA modification in the brain, regulating neural processes and contributing to disease mechanisms. Despite its importance, regional, age-specific and sex-specific m6A patterns in the human brain are still poorly described. Here, we profiled m6A mRNA modifications in five human brain regions (Brodmann areas 9 and 24, and the caudate, hippocampus and thalamus) across 25 individuals of different ages, ranging from 0 to 71 years old. We uncovered widespread regional differences for m6A patterns in the brain, notably in disease-risk genes, while age-related changes were most prominent in the prefrontal cortex. Integrating m6A data with whole-genome sequencing revealed that m6A modifications are associated with disease-related genetic loci. Our work identifies the spatial and temporal variation in m6A modifications and suggests how they could contribute to neurological disorders.
- Open Access
- 10 October 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-19
A novel gene expression stability metric to unveil homeostasis and regulation
We explore the concept of gene expression stability within a homeostatic cell through the gene homeostasis Z-index, a measure that highlights genes under active regulation in response to internal and external stimuli. The Z-index uncovers distinct regulatory activities and patterns driven by a small subset of cells, providing insights that traditional mean-based methods often overlook. By capturing subtle regulatory dynamics, this approach highlights the importance of stability metrics in uncovering detailed gene regulation patterns that underpin cellular adaptation.
- 10 October 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-19
Open AccessA novel gene expression stability metric to unveil homeostasis and regulation
We explore the concept of gene expression stability within a homeostatic cell through the gene homeostasis Z-index, a measure that highlights genes under active regulation in response to internal and external stimuli. The Z-index uncovers distinct regulatory activities and patterns driven by a small subset of cells, providing insights that traditional mean-based methods often overlook. By capturing subtle regulatory dynamics, this approach highlights the importance of stability metrics in uncovering detailed gene regulation patterns that underpin cellular adaptation.
- Open Access
- 14 May 2025
- Published by Elsevier in Cell Genomics
- Vol. 5 (5) , 100875
scPrediXcan integrates deep learning methods and single-cell data into a cell-type-specific transcriptome-wide association study framework
- 14 May 2025
- Published by Elsevier in Cell Genomics
- Vol. 5 (5) , 100875
Open AccessscPrediXcan integrates deep learning methods and single-cell data into a cell-type-specific transcriptome-wide association study framework
- Open Access
- 17 March 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-26
Exploring and mitigating shortcomings in single-cell differential expression analysis with a new statistical paradigm
Differential expression analysis is pivotal in single-cell transcriptomics for unraveling cell-type–specific responses to stimuli. While numerous methods are available to identify differentially expressed genes in single-cell data, recent evaluations of both single-cell–specific methods and methods adapted from bulk studies have revealed significant shortcomings in performance. In this paper, we dissect the four major challenges in single-cell differential expression analysis: excessive zeros, normalization, donor effects, and cumulative biases. These “curses” underscore the limitations and conceptual pitfalls in existing workflows. To address the limitations of current single-cell differential expression analysis methods, we propose GLIMES, a statistical framework that leverages UMI counts and zero proportions within a generalized Poisson/Binomial mixed-effects model to account for batch effects and within-sample variation. We rigorously benchmarked GLIMES against six existing differential expression methods using three case studies and simulations across different experimental scenarios, including comparisons across cell types, tissue regions, and cell states. Our results demonstrate that GLIMES is more adaptable to diverse experimental designs in single-cell studies and effectively mitigates key shortcomings of current approaches, particularly those related to normalization procedures. By preserving biologically meaningful signals, GLIMES offers improved performance in detecting differentially expressed genes. By using absolute RNA expression rather than relative abundance, GLIMES improves sensitivity, reduces false discoveries, and enhances biological interpretability. This paradigm shift challenges existing workflows and highlights the need for careful consideration of normalization strategies, ultimately paving the way for more accurate and robust single-cell transcriptomic analyses.
- 17 March 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-26
Open AccessExploring and mitigating shortcomings in single-cell differential expression analysis with a new statistical paradigm
Differential expression analysis is pivotal in single-cell transcriptomics for unraveling cell-type–specific responses to stimuli. While numerous methods are available to identify differentially expressed genes in single-cell data, recent evaluations of both single-cell–specific methods and methods adapted from bulk studies have revealed significant shortcomings in performance. In this paper, we dissect the four major challenges in single-cell differential expression analysis: excessive zeros, normalization, donor effects, and cumulative biases. These “curses” underscore the limitations and conceptual pitfalls in existing workflows. To address the limitations of current single-cell differential expression analysis methods, we propose GLIMES, a statistical framework that leverages UMI counts and zero proportions within a generalized Poisson/Binomial mixed-effects model to account for batch effects and within-sample variation. We rigorously benchmarked GLIMES against six existing differential expression methods using three case studies and simulations across different experimental scenarios, including comparisons across cell types, tissue regions, and cell states. Our results demonstrate that GLIMES is more adaptable to diverse experimental designs in single-cell studies and effectively mitigates key shortcomings of current approaches, particularly those related to normalization procedures. By preserving biologically meaningful signals, GLIMES offers improved performance in detecting differentially expressed genes. By using absolute RNA expression rather than relative abundance, GLIMES improves sensitivity, reduces false discoveries, and enhances biological interpretability. This paradigm shift challenges existing workflows and highlights the need for careful consideration of normalization strategies, ultimately paving the way for more accurate and robust single-cell transcriptomic analyses.